Companies Dominating the Intramedullary Osteosarcoma Treatment Landscape
- OS Therapies
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- RefleXion
- Novartis International AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Baxter
- Aurobindo Pharma
- Hikma Pharmaceuticals PLC
Browse Key Market Insights with Data Illustration:
In the News
- October 2021 - OS Therapies, a research and clinical-stage biopharmaceutical company announced today the dosing of the "First Patient In" for its lead OST-HER2 (OST31-164) program in a potentially pivotal Phase IIb clinical trial. OST-HER2 has already received Fast-Track and Orphan Designation from the EMA and FDA. The nationwide open-label trial will enroll 39 to 45 Osteosarcoma patients whose cancer has metastasized to the lungs and has been surgically resected.
- February 2023 - The U.S. Food and Drug Administration (FDA) has approved the first marketing authorization for RefleXion Medical's SCINTIXTM biology-guided radiation, a novel treatment that can be used for both early- and late-stage tumors. The CEO and co-founder of the company will be speaking live on the company's website about the groundbreaking potential of SCINTIX therapy for the treatment of cancer.
